SCHEMBL29519632

SCHEMBL29519632

COc1ccc(F)cc1C(=O)N(C(C)C)C(C)C

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PIN1 Q13526 4/20 0.46
AR P10275 1/20 0.43
KDM4E B2RXH2 1/20 0.42
SMN1; SMN2 Q16637 5/20 0.42
RAB9A P51151 2/20 0.42
NPC1 O15118 1/20 0.42
LMNA P02545 1/20 0.42
PKM P14618 1/20 0.42
BCL2L1 Q07817 2/20 0.40
MEN1 O00255 1/20 0.40
MAPT P10636 1/20 0.40
KMT2A Q03164 1/20 0.40
CLK1 P49759 1/20 0.40
CLK2 P49760 1/20 0.40
HTT P42858 1/20 0.40
GAA P10253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19694905 1.00 PIN1 (0.46) PIN1ARKDM4ESMN1; SMN2RAB9A
SCHEMBL25598466 0.89 KDM4E (0.43) PIN1ARKDM4EMEN1KMT2A
SCHEMBL25783048 0.87 KDM4E (0.41) PIN1ARKDM4EMEN1KMT2A
SCHEMBL23529631 0.86 PIN1 (0.42) PIN1ARKDM4ESMN1; SMN2RAB9A
SCHEMBL38652028 0.84 PIN1 (0.41) PIN1ARKDM4ESMN1; SMN2RAB9A
SCHEMBL25783129 0.83 PIN1 (0.46) PIN1KDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL30440324 0.82 KDM4E (0.48) PIN1ARKDM4ESMN1; SMN2RAB9A
SCHEMBL29932506 0.82 KDM4E (0.48) PIN1ARKDM4ESMN1; SMN2RAB9A
SCHEMBL23529573 0.82 KDM4E (0.48) PIN1ARKDM4ESMN1; SMN2RAB9A
SCHEMBL25599736 0.82 KDM4E (0.42) PIN1ARKDM4ESMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240317748-A1 CARBONYL SUBSTITUTED DIAZASPIRO COMPOUNDS AND ITS USE BIONOVA PHARMACEUTICALS LTD. (KY) 2024-09-26 US disclosed
CN-118344372-A Substituted straight-chain spiro derivatives 詹森药业有限公司 2024-07-16 CN disclosed
CN-118255773-A Substituted straight-chain spiro derivatives 詹森药业有限公司 2024-06-28 CN disclosed
CN-118255774-A Substituted straight-chain spiro derivatives 詹森药业有限公司 2024-06-28 CN disclosed
CN-117956992-A MENIN-MLL interaction inhibitors 赛达克斯制药股份有限公司 2024-04-30 CN disclosed
EP-4271676-A1 CARBONYL SUBSTITUTED DIAZASPIRO COMPOUNDS AND ITS USE Bionova Pharmaceuticals (Shanghai) Limited (CN) 2023-11-08 EP disclosed
CN-116829559-A Carbonyl substituted diazaspiro compounds and uses thereof 烨辉医药科技(上海)有限公司 2023-09-29 CN disclosed
CN-112585140-B Optically active azabicyclo derivatives 住友制药株式会社 2023-07-04 CN disclosed
EP-4077312-A1 SUBSTITUTED STRAIGHT CHAIN SPIRO DERIVATIVES Janssen Pharmaceutica NV (BE) 2022-10-26 EP disclosed
CN-114867721-A Substituted straight-chain spiro derivatives 詹森药业有限公司 2022-08-05 CN disclosed
CN-109743875-B Inhibitors of the MENIN-MLL interaction 生命医药有限责任公司 2022-04-29 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240317748-A1 CARBONYL SUBSTITUTED DIAZASPIRO COMPOUNDS AND ITS USE SDHA, PDHA1, GLS PIN1 2427/4885AR 1032/4885KDM4E 1113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.